Commission Implementing Regulation (EU) 2019/707 of 7 May 2019 amending Implementing Regulation (EU) No 540/2011 as regards the extension of the approval periods of the active substances alpha-cypermethrin, beflubutamid, benalaxyl, benthiavalicarb, bifenazate, boscalid, bromoxynil, captan, cyazofamid, desmedipham, dimethoate, dimethomorph, diuron, ethephon, etoxazole, famoxadone, fenamiphos, flumioxazine, fluoxastrobin, folpet, foramsulfuron, formetanate, metalaxyl-m, methiocarb, metribuzin, milbemectin, Paecilomyces lilacinus strain 251, phenmedipham, phosmet, pirimiphos-methyl, propamocarb, prothioconazole, s-metolachlor and tebuconazole
Proposed act with possible EEA relevance
Act under scrutiny by EEA EFTA
Draft Joint Committee Decision (JCD) under consideration
Entry into force of Joint Committee Decision (JCD) pending
Incorporated into the EEA Agreement and in force
Incorporated into the EEA Agreement but no longer in force
Legal status
EU legal act incorporated into the EEA Agreement by a Joint Committee Decision (JCD)
Area (EEA Agreement)
II Technical Regulations, Standards, Testing and Certification
II.XV Dangerous Substances
Joint committee decision (JCD)
298/2019
In force in the EEA
Yes
Legal Documents
Commission Implementing Regulation (EU) 2019/707 of 7 May 2019 amending Implementing Regulation (EU) No 540/2011 as regards the extension of the approval periods of the active substances alpha-cypermethrin, beflubutamid, benalaxyl, benthiavalicarb, bifenazate, boscalid, bromoxynil, captan, cyazofamid, desmedipham, dimethoate, dimethomorph, diuron, ethephon, etoxazole, famoxadone, fenamiphos, flumioxazine, fluoxastrobin, folpet, foramsulfuron, formetanate, metalaxyl-m, methiocarb, metribuzin, milbemectin, Paecilomyces lilacinus strain 251, phenmedipham, phosmet, pirimiphos-methyl, propamocarb, prothioconazole, s-metolachlor and tebuconazole
Framkvæmdarreglugerð framkvæmdastjórnarinnar (ESB) 2019/707 frá 7. maí 2019 um breytingu á framkvæmdarreglugerð (ESB) nr. 540/2011 að því er varðar framlengingu á samþykkistímabilum fyrir virku efnin alfasýpermetrín, beflúbútamíð, benalaxýl, benþíavalíkarb, bífenasat, boskalíð, brómoxýníl, kaptan, sýasófamíð, desmedífam, dímetóat, dímetómorf, díúrón, etefón, etoxasól, famoxadón, fenamífos, flúmíoxasín, flúoxastróbín, fólpet, foramsúlfúrón, formetanat, metalaxýl-m, metíókarb, metríbúsín, milbemektín, Paecilomyces lilacinus af stofni 251, fenmedífam, fosmet, pírimífosmetýl, própamókarb, próþíókónasól, s-metólaklór og tebúkónasól
Durchführungsverordnung (EU) 2019/707 der Kommission vom 7. Mai 2019 zur Änderung der Durchführungsverordnung (EU) Nr. 540/2011 hinsichtlich der Verlängerung der Laufzeit der Genehmigung für die Wirkstoffe Alpha-Cypermethrin, Beflubutamid, Benalaxyl, Benthiavalicarb, Bifenazat, Boscalid, Bromoxynil, Captan, Cyazofamid, Desmedipham, Dimethoat, Dimethomorph, Diuron, Ethephon, Etoxazol, Famoxadon, Fenamiphos, Flumioxazin, Fluoxastrobin, Folpet, Foramsulfuron, Formetanat, Metalaxyl-M, Methiocarb, Metribuzin, Milbemectin, Paecilomyces lilacinus Stamm 251, Phenmedipham, Phosmet, Pirimiphos-methyl, Propamocarb, Prothioconazol, S-Metolachlor und Tebuconazol
Kommisjonens gjennomføringsforordning (EU) 2019/707 av 7. mai 2019 om endring av gjennomføringsforordning (EU) nr. 540/2011 med hensyn til forlengelse av godkjenningsperioden for de aktive stoffene alfa-cypermetrin, beflubutamid, benalaksyl, bentiavalikarb, bifenazat, boskalid, bromoksynil, kaptan, cyazofamid, desmedifam, dimetoat, dimetomorf, diuron, etefon, etoksazol, famoksadon, fenamifos, flumioksazin, fluoksastrobin, folpet, foramsulfuron, formetanat, metalaksyl-m, metiokarb, metribuzin, milbemektin, Paecilomyces lilacinus stamme 251, fenmedifam, fosmet, pirimifos-metyl, propamokarb, protiokonazol, s-metolaklor og tebukonazol
History
Disclaimer: EEA-Lex is provided for information purposes only. The information is not guaranteed or promised to be current or complete and is not intended to replace any applicable legal sources.